Phase 2 study examines OFF time improvement in Parkinson's Disease with solengepras treatment, indicating potential patient benefits.
To study the characteristics of OFF time and the impact of solengepras treatment on the patient experience in a Phase 2 study in Parkinson’s Disease (PD).
No takes yet. Share an insight, caveat, or question.
Hauser et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: